GeoVax Labs, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; balance-sheet comparisons are with December 31, 2015. GeoVax is a clinical-stage biotechnology company developing vaccines for HIV, hemorrhagic fever viruses, Zika, and cancer immunotherapy. It had no approved products and reported grant revenue, not product sales.
Financial performance and liquidity
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Grant revenue | $47,600 | $103,424 |
| Research and development expense | $438,004 | $403,629 |
| General and administrative expense | $906,505 | $401,441 |
| Total operating expenses | $1,344,509 | $805,070 |
| Net loss | $1,296,279 | $700,454 |
| Basic and diluted loss per share | $0.04 | $0.02 |
| Net cash used in operations | $629,064 | $618,882 |
Cash and cash equivalents were $669,482 at March 31, down from $1,060,348 at year-end. Working capital was $542,584, versus $1,109,985. Total assets were $796,452 and current liabilities were $166,445. The filing reports no long-term debt or committed credit lines. Gross margin is not applicable to the reported grant-funded activity; the filing does not present a product-sales margin.
Material changes and notable items
- Net loss increased by about $596,000 year over year. General and administrative expense rose by about $505,000, largely reflecting stock-based compensation, including a $469,799 warrant-modification charge reported in the expense breakdown.
- Research and development expense increased by about $34,000, while grant revenue declined by about $56,000. Grant revenue is recognized as related costs are incurred.
- Financing provided $238,198, compared with $2.68 million in Q1 2015. GeoVax received the 2016 proceeds after amending Series E warrants and issuing 3,664,588 shares upon exercise. Separately, 132 Series C preferred shares converted into 1.4 million common shares.
- At March 31, 37.0 million common shares were outstanding; 52.8 million warrants remained outstanding. As of May 3, common shares issued and outstanding were 37,015,401.
Outlook, risks, and contingencies
- Management said existing cash and grant commitments were expected to fund planned operations only through the third quarter of 2016. The filing states there is substantial doubt about the company’s ability to continue as a going concern beyond that point; management’s fundraising plans do not eliminate that doubt.
- GeoVax was seeking grants, clinical-trial support, philanthropic funding, and potentially equity financing or warrant exercises. Funding may not be available on favorable terms or at all; a shortfall could force delays, reductions, or termination of programs.
- In April 2016, after quarter-end, NIH awarded a two-year SBIR project with a total budget of $1,398,615; the initial first-year award was $740,456. The company also reported $52,869 of approved grant funds remaining at March 31.
- Management expected an NIH-funded Phase 1 HIV vaccine trial to begin in mid-2016, but timing was uncertain. Funding for a proposed direct move to a Phase 2b efficacy trial was not assured. Development, clinical-trial, manufacturing, and regulatory outcomes remain uncertain, and the company may never generate significant product revenue.
- Remaining 2016 lease payments were $111,782; other unrecorded purchase commitments were approximately $5,000. No legal proceedings were reported. The company stated there were no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Near-term funding runway and the availability, timing, and terms of additional financing, including the effect of potential equity dilution.
- Clinical-trial plans and funding, particularly the timing of the proposed Phase 1 trial and whether a Phase 2b program can be financed.
- The warrant-modification compensation disclosure: the expense breakdown reports $469,799, while another sentence in the filing describes $238,198 as stock-based compensation related to the modifications. Confirm the intended accounting amount and reconciliation.
- Whether the April NIH award and remaining grant funds are sufficient to support operations and planned research activity beyond the stated third-quarter 2016 runway.